Human
APIS

Experts in developing
high quality pharmaceutical active ingredients

We develop, produce and market active ingredients for pharmaceutical and biotechnological industries to more than 70 countries and 3,000 clients.

Our wide experience backs us up

Contact us and we will provide you with details of our extensive product portfolio.

Strategic
APIS

  • AVIBACTAM – ANTIBIOTIC
  • ALENDRONATE Na – ANTIOSTEOPOROTIC
  • ALFUZOSIN – BENING PROSTATIC HYPERPLASIA
  • AMITRIPTYLINE HCl – ANTIDEPRESSANT
  • AMLODIPINE BESYLATE – ANTIHYPERTENSIVE
  • ANASTROZOL – ANTINEOPLASTIC&IMMUNOMODULATOR
  • ARIPIPRAZOLE TYPE 1 – ANTIPSICOTIC
  • ATOMOXETINE HCl – ANTIDEPRESSANT
  • ATORVASTATIN Ca FORM 1 – ANIHYPERLIPIDIC
  • BACLOFEN – ANTINEOPLASTIC&IMMUNOMODULATOR
  • BEMPEDOIC ACID – ANTIHYPERCHOLESTEROLEMIC
  • BOSENTAN MONOHYDRATE – CARDIOTONIC
  • BUPROPION HCl – ANTIDEPRESSANT
  • CARVEDILOL – CARDIOVASCULAR SYSTEM
  • CELECOXIB – ANTIINFLAMATORY
  • CLARITHROMYCIN – ANTIBIOTIC
  • CLINDAMYCIN HCL – ANIINFECTIVES
  • CHLORHEXIDINE BASE – DESINFECTANT
  • CHLORHEXIDINE GLUCONATE – DESINFECTANT
  • CLOMIPRAMINE – ANTIDEPRESSANT
  • CLOZAPINE – ANTIPSICOTIC
  • CRISABOROLE – DERMATITIS
  • DABIGATRAN – ANTICLOTTING
  • DAZOXIN – RENAL MALFUNCTION
  • DESLORATADINE – ANTIHISTAMINIC
  • DEXTRANOMER – WOUND HEALER
  • ELAGOLIX – ENDOMETRIOSIS
  • EMPAGLIFLOZIN – RENAL MALFUNCTION
  • ESCITALOPRAM OXALATE – ANTIDEPRESSANT
  • ETHAMBUTOL – ANTITUBERCULOSIS
  • FLUOXETINE HCl – ANTIDEPRESSANT
  • LASMIDITAN – MIGRAINE
  • LEVOCETIRIZINE – ANTIHISTAMINIC
  • GEMFIBROZIL – ANTIIPEMIC
  • GLIMEPIRIDE – METABOLISM
  • GLIGENCLAMYDE / GLYBURIDE – ANTIDIABETIC
  • HALOPERIDOL BASE/DECONATE – ANTIPSICOTIC
  • HYDRALAZINE – ANTIHYPERTENSIVE
  • LABETALOL – ANTIHYPERTENSIVE
  • LIFITEGRAST – DRY EYE SYNDROME
  • LORATADINE – ANTIHISTAMINIC
  • METOCARBAMOL – MUSCULO-SKELETAL
  • MESALAMINE – ANTIINFLAMATORY
  • MINOCYCLINE – ANIINFECTIVES
  • NAPROXEN – MUSCULO-SKELETAL
  • NATEGLINIDE – ANTIDIABETIC
  • NEBIVOLOL – ANTIHIPERTENSIVE
  • NITROFURANTOIN MACROCRYTAL – ANTIBIOTIC
  • OCLACITINIB – ANTINEOPLASTIC&IMMUNOMODULATOR
  • O-DESMETHYL-VENLAFAXINE – ANTIDEPRESSANT
  • OLANZAPINE – ANTIDEPRESSANT
  • OLMESARTAN – ANTIHIPERTENSIVE
  • ONDANSETRON HCl – ANTIEMETIC
  • OXYTETRACYCLINE CALCIUM – ANIINFECTIVES
  • OXYTETRACYCLINE HCl – ANIINFECTIVES
  • PALIPERIDONE – ANTIPSICOTIC
  • PANTOPRAZOL – PPI
  • PRAZOSIN – ANTIHYPERTENSIVE
  • PREGABALIN – CENTRAL NERVOUS SYSTEM
  • PROPANOLOL – CARDIOVASCULAR SYSTEM
  • QUETIAPINE FUMARATE – CENTRAL NERVOUS SYSTEM
  • RALOXIFEN HCl – ANTIOSTEOPOROTIC
  • RANOLAZINE – ANTIANGINAL
  • REVEFENAZIN – CRONIC OBSTRUCTIVE PULMONARY
  • ROPINIROL – ANTIPARKINSON
  • ROSUVASTATIN – METABOLISM
  • SACUBITRIL – CARDIOVASCULAR SYSTEM
  • SILDENAFIL CITRATE – ERECTIL DISFUNTION
  • SITAGLIPTINE HCl – ANTIHYPERCHOLESTEROLEMIC
  • SITAGLIPTINE P – ANTIHYPERCHOLESTEROLEMIC
  • SOLIFENACIN SUCCINATE – OVER REACTIVE BLADDER
  • SUCCINYLCHOLINE – SKELETAL MUSCLE RELAXANT
  • SUGAMMADEX Na – CNS AGENT
  • TAFAMIDIS MEGLUMINE – CARDIOVASCULAR SYSTEM
  • TAVABOROLE – ANTIFUNGAL
  • TERAZOSIN – BENING PROSTATIC HYPERPLASIA
  • TETRACYCLINE – ANIINFECTIVES
  • TETRACYCLINE HCl – ANIINFECTIVES
  • TICAGRELOR – CARDIOVASCULAR SYSTEM
  • UPADACITINIB – ANTINEOPLASTIC&IMMUNOMODULATOR
  • URSODIOL – ANTICHOLETITHIC
  • VALSARTAN SACUBITRIL – CARDIOVASCULAR SYSTEM
  • VELAFAXINE HCl – ANTIDEPRESSANT
  • VILDAGLIPTIN – ANTIDIABETIC

Research
& Development

API

USE

EXPECTED GENERIC
LAUNCH IN EUROPE

OZENOXACINANTIBIOTICOCT 2029
CEFIDEROCOLANTIBIOTICOCT 2034
TEDIZOLID PHOSPHATEANTIBIOTICDEC 2029
ERAVACYCLINE DIHYDROCHLORIDEANTIBIOTICSEPT 2033
OLAPARIBONCOLOGYMAR 2029
ABEMACICLIBONCOLOGYDEC 2029
FOSTAMATINIBONCOLOGYJAN 2031
IBRUTINIBONCOLOGYOCT 2029
TRAMETINIBONCOLOGYJUL 2029
UPADACITINIBRHEUMATOID ARTHRITISDEC 2034
FILGOTINIBRHEUMATOID ARTHRITISSEPT 2030
SEMAGLUTIDEDIABETESFEB 2028
EMPAGLIFLOZINDIABETESMAY 2029
CANAGLIFLOZINDIABETESNOV 2028
BEDAQUILINE FUMARATETUBERCULOSISJUL 2028
LEMBOREXANTINSOMNIASEPT 2031
MIRABEGRONURINARY INCONTINENCEJAN 2028
OZANIMODMULTIPLE SCLEROSISMAY 2030
OPICAPONEPARKINSON'S DISEASEJUN 2031
NALOXEGOLOPIOID-INDUCED CONSTIPATIONDEC 2029
VERICIGUATCARDIOVASCULARJUL 2031

Items covered by valid patents are not offered or supplied for commercial use.
Products under patent are available for R&D use only.

Other products developed
& manufactured under exclusive basis

Specialized products with studies
and available clinical data

If you can´t find the product you are looking for,
or you are interested in developing a new product,
please contact us.

+34 91 344 68 90
info@suanfarma.com